PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain

2023-12-11
(Press-News.org) Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year. At the same time, the study shows that remaining on the drug not only promotes additional weight loss but preserves improvements in metabolic and cardiovascular health.

The results from the SURMOUNT-4 study, which appeared Dec. 11 in JAMA and was sponsored by Eli Lilly and Company, demonstrated that the drug can substantially help people struggling with health issues related to their weight, but it is not a quick-fix to weight loss.

“Obesity is a leading driver of many diseases that we spend our time treating in medicine; illnesses like hypertension, heart disease, diabetes and fatty liver disease are either caused by or worsened by obesity,” said lead study author Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research and director of the Comprehensive Weight Control Center, which is part of the Division of Endocrinology, Diabetes, and Metabolism at Weill Cornell Medicine. “The fact that we now have drugs that are proving to be effective is exciting and rewarding.”

Diabetes Drug Promotes Weight Loss Tirzepatide is part of a new class of drugs called called GLP-1 receptor agonists that were developed to treat type 2 diabetes. Besides controlling blood sugar, the drugs also resulted in weight loss, so pharma companies created specific formulations to help patients shed pounds.

In 2022, a phase 3 randomized, controlled clinical trial demonstrated that tirzepatide led to a 20 percent reduction in body weight over 72 weeks. The findings prompted the U.S. Food and Drug Administration to approve the drug last month, with the trade name Zepbound, for weight loss in individuals with a body mass index (BMI) of 30 or higher—or for those with a BMI of 27 or greater who also had health conditions such as high cholesterol or hypertension.

Although the initial effects were dramatic, the researchers were uncertain whether the weight loss would persist beyond the period of active treatment. To find out, they launched the SURMOUNT-4 trial, which was conducted at 70 sites in Argentina, Brazil, Taiwan and the United States between March 2021 and May 2023. The participants took a maximum tolerated dose of tirzepatide for 36 weeks, which yielded the expected weight reduction of 20.9 percent with improvements in blood pressure, blood sugar metrics and lipid levels.

Then 670 eligible participants were randomly assigned to either continue with the tirzepatide for an additional year (52 weeks) or to switch to a placebo. Those who continued on tirzepatide lost an additional 5.5 percent versus the placebo group which regained 14 percent of their weight.

Though the placebo group was still almost 10 percent lighter than their initial weight, the improvements in cardiometabolic risk factors had been reversed. Relative to placebo, tirzepatide was associated with significant improvements in BMI, lipid levels, diabetes indicators and blood pressure.

“Those who went on the placebo regained about half the weight they had lost,” said Dr. Aronne, who is also an internist specializing in diabetes and obesity at NewYork-Presbyterian/Weill Cornell Medical Center. “Whereas those who continued on the drug lost another 5 percent, so their overall weight loss was about 25 percent.”

The findings indicate that people may need to remain on tirzepatide to keep off the pounds. “If you stop the medication, you regain the weight. There’s no question that will happen,” said Dr. Aronne. But that shouldn’t be surprising. “Obesity is a chronic condition, like diabetes or high blood pressure. So, it must be treated chronically.”

The researchers noted that they didn’t evaluate the effects of intensive behavioral therapy on the maintenance of body weight reduction, which could make a difference in preventing weight regain after coming off the drug. 

Tirzepatide Mimics Natural Hormones that Foster Feeling Full Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion. It also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain harboring GLP-1 receptors to signal satiety.

“Instead of counting calories, the medicine helps a person eat less because it signals to the brain that you’re full,” said Dr. Aronne. “The dual mechanism of action helps overcome the plateau phenomenon that is seen at some point and produces additive weight loss.”

Since the drug mimics hormones that are produced in the gastrointestinal system, side effects tended to be nausea, vomiting, diarrhea or constipation and resolved with time. The study had few people dropout because of side effects.

“People feel much better when they lose this kind of weight, so they are extremely enthusiastic about these treatments. But they also should realize this may require them to stay on the drug long term,” said Dr. Aronne. Further studies will need to assess the long-term risks and benefits associated with these drugs, especially considering the potential for their lifelong use.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. Dr. Louis J. Aronne serves as a paid advisory board member for Eli Lilly and Company. For further information, see the profile for Dr. Louis Aronne.

END


ELSE PRESS RELEASES FROM THIS DATE:

Scholars named for research leadership program to increase diversity in clinical trials

2023-12-11
DALLAS, Dec. 11, 2023 — The American Heart Association — the world’s leading voluntary organization dedicated to a world of longer, healthier lives for all — continues its commitment to address the lack of diversity, equity and inclusion in clinical trials for medical research with the selection of two early-career scientists for the inaugural Robert A. Winn Clinical Investigator Leadership Award in Cardiovascular Research (Winn CILA-CV). The award is sponsored by the Bristol Myers ...

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows
2023-12-11
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting. The combination was generally well-tolerated, a notable finding according to Craig A. Portell, MD, who presented the data for PrECOG, LLC, at the 65th American Society of Hematology (ASH) Meeting and Exposition in San Diego, California, ...

Schedule of sessions and press registration information now available for the ILSI 2024 Annual Meeting and Science Symposium

2023-12-11
FOR IMMEDIATE RELEASE December 11, 2023 ILSI Global press contact: Katherine Broendel +1 (202) 659-0074 Ext. 175 kbroendel@ilsi.org WASHINGTON—The International Life Sciences Institute (ILSI) has announced that its Annual Meeting, Technologies and Climate Change: Shaking up 21st Century Food Systems – Promises and Pitfalls, will take place in Clearwater, Florida, 21-24 January 2024. ILSI's Annual Meeting will feature scientific presentations, professional development and networking opportunities for researchers, academics, industry leaders, nongovernmental organizations, as well as public sector and ...

Madden studying merchants, maps & manuscripts of late medieval world

2023-12-11
Amanda Madden, Assistant Professor, History and Art History; Director, Geospatial History, received funding for the project: "La sfera (The Globe): A Late Medieval World of Merchants, Maps, & Manuscripts." In collaboration with the project team, Co-PI Madden, Senior Developer Jason Heppler, and the Roy Rosenzweig Center for History and New Media (RRCHNM) propose to design and develop a digital edition of the text, including the user interface and data pipeline.  The NEH grant will fund the development of a dynamic, interactive ...

New project will take a step towards answering whether gravity is quantum

New project will take a step towards answering whether gravity is quantum
2023-12-11
Scientists are developing an experiment to test whether gravity is quantum In quantum mechanics, which describes the behaviour of atoms and molecules –objects behave differently to everything we know: they can be in a quantum superposition of being in two places at the same time Now, scientists are investigating a way to determine whether gravity operates in this way, by levitating micro diamonds in a vacuum If gravity is quantum, it will ‘entangle’ the diamonds – an intriguing phenomenon which strongly links two objects in ways impossible in everyday life This research will help ...

Stem cell study reveals how infantile cystinosis causes kidney failure – and how to cure it

Stem cell study reveals how infantile cystinosis causes kidney failure – and how to cure it
2023-12-11
BUFFALO, N.Y. – University at Buffalo research has identified how a misstep in the genesis of a key component of the kidney causes infantile cystinosis, a rare disease that significantly shortens the lifespan of patients. Published Nov. 30 in the International Journal of Molecular Sciences, the work reveals that the mechanisms that cause the disease could be addressed and potentially cured through the genome-editing technique CRISPR. That could make kidney transplants, the most effective treatment currently available for these patients, unnecessary. Infantile ...

Raz developing advanced model-based tools for portfolio management

2023-12-11
Raz Developing Advanced Model-Based Tools For Portfolio Management Ali Raz, Professor, Systems Engineering and Operations Research (SEOR), received funding for the project: "Advanced Model-Based Tools for Portfolio Management and Analytic: System Architecture and Multi-Attribute Decision Making for Integrating Autonomy Phase 2 (AIRC RT-1081.07.5)." Raz is supporting Purdue University and Georgia Tech Research Institute (GTRI) in the enhancement of the IAPR System-of-systems (SoS) tool suite. Raz received $20,500 from Stevens Institute of Technology on a subaward from the U.S. Department of Defense for ...

SETI Institute unveils two prestigious postdoctoral fellowships: the Baruch S. Blumberg Fellowship and the William J. Welch Fellowship

SETI Institute unveils two prestigious postdoctoral fellowships: the Baruch S. Blumberg Fellowship and the William J. Welch Fellowship
2023-12-11
December 11, 2023, Mountain View, CA -- The SETI Institute announced today the establishment of a new postdoctoral research fellowship program funded by its transformative bequest from Qualcomm Co-founder, Franklin Antonio.  The first two fellowships are being announced in conjunction with the American Geophysical Union Conference (AGU) being held this week in San Francisco.  The Baruch S. Blumberg Postdoctoral Fellowship for Astrobiology and the William J. Welch Postdoctoral Fellowship for SETI and Technosignatures ...

Alaskan allies: Communities unite to protect the areas they love

Alaskan allies: Communities unite to protect the areas they love
2023-12-11
URBANA, Ill. — Natural resource management decisions in protected areas impact more than the wildlife and landscapes they’re charged to conserve. They also affect neighbors, who could otherwise hunt, build, or recreate as they choose on their own land. For decades, community members primarily voiced their opinions through brief and impersonal public comment periods. But an initiative led by environmental social scientists at the University of Illinois Urbana-Champaign is putting a new spin on neighborly communication.  “Historically, public land management ...

Researchers find promising candidate to treat irreversible lung and eye diseases in extremely premature infants

Researchers find promising candidate to treat irreversible lung and eye diseases in extremely premature infants
2023-12-11
Philadelphia, December 11, 2023 – Advancements in the care of premature babies are leading to improved survival rates. However, the incidence of neonatal diseases with life-long consequences such as bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) is increasing. A novel study has implicated granulocyte colony-stimulating factor (G-CSF) in both BPD and ROP, making it a promising therapeutic candidate. The results appear in The American Journal of Pathology, published by Elsevier. BPD, also called chronic lung disease of immaturity, afflicts approximately one third of all extremely ...

LAST 30 PRESS RELEASES:

Fig trees convert atmospheric CO2 to stone

Intra-arterial tenecteplase for acute stroke after successful endovascular therapy

Study reveals beneficial microbes that can sustain yields in unfertilized fields

Robotic probe quickly measures key properties of new materials

Climate change cuts milk production, even when farmers cool their cows

Frozen, but not sealed: Arctic Ocean remained open to life during ice ages

Some like it cold: Cryorhodopsins

Demystifying gut bacteria with AI

Human wellbeing on a finite planet towards 2100: new study shows humanity at a crossroads

Unlocking the hidden biodiversity of Europe’s villages

Planned hydrogen refuelling stations may lead to millions of euros in yearly losses

Planned C-sections increase the risk of certain childhood cancers

Adults who have survived childhood cancer are at increased risk of severe COVID-19

Drones reveal extreme coral mortality after bleaching

New genetic finding uncovers hidden cause of arsenic resistance in acute promyelocytic leukemia

Native habitats hold the key to the much-loved smashed avocado’s future

Using lightning to make ammonia out of thin air

Machine learning potential-driven insights into pH-dependent CO₂ reduction

Physician associates provide safe care for diagnosed patients when directly supervised by a doctor

How game-play with robots can bring out their human side

Asthma: patient expectations influence the course of the disease

UNM physician tests drug that causes nerve tissue to emit light, enabling faster, safer surgery

New study identifies EMP1 as a key driver of pancreatic cancer progression and poor prognosis

XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

Flexible, eco-friendly electronic plastic for wearable tech, sensors

Can the Large Hadron Collider snap string theory?

Stuckeman professor’s new book explores ‘socially sustainable’ architecture

Synthetic DNA nanoparticles for gene therapy

New model to find treatments for an aggressive blood cancer

Special issue of Journal of Intensive Medicine analyzes non-invasive respiratory support

[Press-News.org] Tirzepatide enhances weight loss with sustained treatment but discontinuation leads to weight regain